<div id="readability-page-1"><div><p>China Medical System Holdings (SEHK:867) has put fresh numbers on the table for FY 2025, posting first half revenue of C¥4.0b and basic EPS of C¥0.39, alongside trailing twelve month revenue of C¥7.9b and EPS of C¥0.68. The company has seen revenue move from C¥3.6b in the first half of FY 2024 to C¥4.0b in the first half of FY 2025 and trailing revenue shift from C¥7.5b to C¥7.9b, with basic EPS across reported halves ranging between C¥0.29 and C¥0.39. For you as an investor, the key question now is how these revenue and EPS figures sit against pressure on margins and what that balance suggests about the quality of the current earnings mix.</p> <p>See our full analysis for China Medical System Holdings.</p><p>With the headline figures set, the next step is to weigh these results against the prevailing narratives around growth, profitability and risk to see which stories hold up and which ones the latest numbers challenge.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cafcb699-b11b-4393-8195-53704c82fc0e/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTAzLTE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cafcb699-b11b-4393-8195-53704c82fc0e/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTAzLTE4"/><figcaption>SEHK:867 Revenue &amp; Expenses Breakdown as at Mar 2026</figcaption></figure> <h2>11.4% revenue growth versus market</h2> <ul> <li>Trailing revenue is reported at C¥8.2b, with revenue growth of 11.4% per year compared with a Hong Kong market figure of 8.3% per year.</li> <li>What stands out for the bullish view is that this 11.4% revenue growth and forecast earnings growth of about 21.9% per year sit alongside high described earnings quality, even though earnings over the past five years declined at roughly 14.7% per year.     <ul> <li>Supporters point to the trailing 12 month net income of about C¥1.5b against C¥8.2b of revenue as evidence that the business is still converting a meaningful slice of sales into profit.</li> <li>At the same time, critics can point to the negative earnings growth over the last year and the long term earnings decline to question how durable those growth forecasts are.</li> </ul> </li> </ul> <h2>Margins slip from 21.7% to 18.1%</h2> <ul> <li>Net profit margin over the last 12 months is given as 18.1%, compared with 21.7% in the prior year, alongside first half FY 2025 net income of C¥941.2m on C¥4.0b of revenue.</li> <li>Bears focus on this margin move and the negative trailing earnings growth as a challenge to any simple growth story, even though revenue has been growing at 11.4% per year.     <ul> <li>The shift from a 21.7% margin to 18.1% sits next to trailing 12 month net income of C¥1.5b on C¥8.2b of revenue, which still leaves room for profitability but at a lower level than the prior year.</li> <li>With basic EPS across the last three reported halves ranging between C¥0.29 and C¥0.39, skeptics can argue that recent profitability has been uneven compared with the stronger margin history referenced in the data.</li> </ul> </li> </ul> <h2>P/E of 19.5x and DCF fair value</h2> <ul> <li>The shares trade on a trailing P/E of 19.5x, which is below the peer average of 24.5x but above the Hong Kong pharmaceuticals industry average of 12.3x. The current share price of HK$13.72 is set against an analyst target of HK$17.66 and a DCF fair value of HK$34.31.</li> <li>Supporters of the more optimistic view argue that trading well below the HK$34.31 DCF fair value and below the HK$17.66 analyst target points to valuation support, yet the mixed P/E comparison and margin compression mean the case leans heavily on those growth forecasts being met.     <ul> <li>On one side, the stock is described as about 60% below the DCF fair value estimate and analysts as a group imply around 28.7% upside from the current HK$13.72 price.</li> <li>On the other side, a 19.5x P/E that is higher than the 12.3x industry average, alongside an 18.1% net margin that is lower than last year, gives investors clear reasons to compare valuation against execution very closely.</li> </ul> </li> </ul> <p>For a fuller picture of how different investors are interpreting these numbers and where they think the story goes next, it is worth checking how the community frames the bull and bear cases for this business <strong>📊 Read the what the Community is saying about China Medical System Holdings.</strong></p> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on China Medical System Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>If the mixed signals around revenue growth, margins and valuation leave you on the fence, treat that as a cue to review the numbers directly and decide how they stack up for your own portfolio. To see what is driving optimism and where those potential rewards are concentrated, take a closer look at the 3 key rewards.</p> <h2>See What Else Is Out There</h2> <p>China Medical System Holdings faces pressure from slipping net margins, uneven recent EPS figures and a P/E above the industry average despite past earnings declines.</p> <p>If that mix of margin pressure and valuation leaves you cautious, broaden your watchlist and quickly compare alternatives using the 229 high quality undervalued stocks.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

00867

513700

<p>China Medical System Holdings (SEHK:867) reported FY 2025 first half revenue of C¥4.0b and basic EPS of C¥0.39, showing growth from C¥3.6b and C¥0.29 in FY 2024. However, net profit margin declined from 21.7% to 18.1%, raising concerns about earnings quality despite an 11.4% revenue growth. The stock trades at a trailing P/E of 19.5x, below the peer average, with a current price of HK$13.72 against an analyst target of HK$17.66 and a DCF fair value of HK$34.31. Investors are advised to consider long-term trends and mixed signals in revenue growth and margins.</p>

China Medical System Holdings SEHK 867 Margin Decline Tests Bullish Growth Narrative